EXAS
Price
$52.34
Change
-$0.20 (-0.38%)
Updated
Jun 18, 04:59 PM (EDT)
Capitalization
12.78B
48 days until earnings call
ILMN
Price
$90.30
Change
+$0.83 (+0.93%)
Updated
Jun 18, 04:59 PM (EDT)
Capitalization
21.09B
50 days until earnings call
Interact to see
Advertisement

EXAS vs ILMN

Header iconEXAS vs ILMN Comparison
Open Charts EXAS vs ILMNBanner chart's image
Exact Sciences
Price$52.34
Change-$0.20 (-0.38%)
Volume$236.53K
Capitalization12.78B
Illumina
Price$90.30
Change+$0.83 (+0.93%)
Volume$23.66K
Capitalization21.09B
EXAS vs ILMN Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. ILMN commentary
Jun 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and ILMN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2025
Stock price -- (EXAS: $52.54 vs. ILMN: $89.47)
Brand notoriety: EXAS and ILMN are both notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 87% vs. ILMN: 118%
Market capitalization -- EXAS: $12.78B vs. ILMN: $21.09B
EXAS [@Medical Specialties] is valued at $12.78B. ILMN’s [@Medical Specialties] market capitalization is $21.09B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileILMN’s FA Score has 0 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • ILMN’s FA Score: 0 green, 5 red.
According to our system of comparison, EXAS is a better buy in the long-term than ILMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 4 TA indicator(s) are bullish while ILMN’s TA Score has 5 bullish TA indicator(s).

  • EXAS’s TA Score: 4 bullish, 4 bearish.
  • ILMN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ILMN is a better buy in the short-term than EXAS.

Price Growth

EXAS (@Medical Specialties) experienced а -6.48% price change this week, while ILMN (@Medical Specialties) price change was +1.69% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.96%. For the same industry, the average monthly price growth was -0.64%, and the average quarterly price growth was +1.36%.

Reported Earning Dates

EXAS is expected to report earnings on Aug 05, 2025.

ILMN is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (-2.96% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ILMN($21.1B) has a higher market cap than EXAS($12.8B). EXAS YTD gains are higher at: -6.496 vs. ILMN (-33.046). EXAS has higher annual earnings (EBITDA): 29.3M vs. ILMN (-608M). ILMN has more cash in the bank: 1.05B vs. EXAS (778M). ILMN has less debt than EXAS: ILMN (2.26B) vs EXAS (2.56B). ILMN has higher revenues than EXAS: ILMN (4.5B) vs EXAS (2.5B).
EXASILMNEXAS / ILMN
Capitalization12.8B21.1B61%
EBITDA29.3M-608M-5%
Gain YTD-6.496-33.04620%
P/E RatioN/A49.50-
Revenue2.5B4.5B56%
Total Cash778M1.05B74%
Total Debt2.56B2.26B113%
FUNDAMENTALS RATINGS
EXAS vs ILMN: Fundamental Ratings
EXAS
ILMN
OUTLOOK RATING
1..100
529
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
5159
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for ILMN (77). This means that EXAS’s stock grew somewhat faster than ILMN’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ILMN (100). This means that EXAS’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's SMR Rating (95) in the Biotechnology industry is in the same range as EXAS (97). This means that ILMN’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (51) in the Biotechnology industry is in the same range as ILMN (59). This means that EXAS’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's P/E Growth Rating (94) in the Biotechnology industry is in the same range as EXAS (100). This means that ILMN’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASILMN
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 30 days ago
70%
Bullish Trend 9 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 17 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
62%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CBL25.240.55
+2.23%
CBL & Associates Properties
SPRO2.900.05
+1.75%
Spero Therapeutics
AMED97.510.17
+0.17%
Amedisys
LII537.47-6.49
-1.19%
Lennox International
EQ0.33-0.01
-2.97%
Equillium

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-1.43%
QGEN - EXAS
55%
Loosely correlated
-1.90%
RGEN - EXAS
55%
Loosely correlated
-4.03%
CDNA - EXAS
33%
Loosely correlated
+2.36%
ILMN - EXAS
33%
Loosely correlated
-0.86%
BRKR - EXAS
33%
Poorly correlated
-3.74%
More

ILMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with A. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ILMN
1D Price
Change %
ILMN100%
-0.86%
A - ILMN
64%
Loosely correlated
-2.46%
RVTY - ILMN
63%
Loosely correlated
-2.27%
BRKR - ILMN
61%
Loosely correlated
-3.74%
BIO - ILMN
59%
Loosely correlated
-0.54%
MTD - ILMN
58%
Loosely correlated
-2.73%
More